Germany to recognise Bharat Biotech's COVAXIN for travel from June 1
Wednesday, July 6, 2022
  • Circulation
  • Advertise
  • About Us
  • Contact Us
Organiser
  • ‌
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Sports
  • Business
  • More
    • RSS in News
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
SUBSCRIBE
No Result
View All Result
Organiser
  • ‌
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Sports
  • Business
  • More
    • RSS in News
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
No Result
View All Result
Organiser
No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Opinion
  • Analysis
  • Culture
  • Defence
  • RSS in News
  • Subscribe
Home World

Germany to recognise Bharat Biotech’s COVAXIN for travel from June 1

German Ambassador to India, Walter J Lindner said the German government for recognising the WHO-listed Bharat Biotech's COVID vaccine, COVAXIN, for travel to the country starting June 1.

WEB DESK by WEB DESK
May 26, 2022, 11:55 am IST
in World
COVAXIN

COVAXIN

Share on FacebookShare on TwitterTelegramEmail

New Delhi [India]: German Ambassador to India, Walter J Lindner, on Thursday (May 26) hailed the German government for recognising the WHO-listed Bharat Biotech’s COVID vaccine, COVAXIN, for travel to the country starting June 1.

In November last year, World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2.

Taking to Twitter, the Ambassador to Germany and Bhutan Lindner wrote, “Very happy that GER government just decided to recognise WHO-listed Covaxin for travels to GER, starting June 1! This Embassy has been pushing very actively for such decision (because of Covid-backlogs visa sections have longer waiting periods than normal, please have patience).”

Download Organiser App

Very happy that GER government just decided to recognize WHO-listed Covaxin for travels to GER, starting June 1! This Embassy has been pushing very actively for such decision (because of Covid-backlogs visa sections have longer waiting periods than normal, please have patience) pic.twitter.com/LFKqlyYzaW

— Walter J. Lindner (@WalterJLindner) May 26, 2022

WHO’s EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

“This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic,” said Dr Mariangela Simao, WHO Assistant-Director General for Access to Medicines and Health Products said.

In April, the Drugs Controller General of India (DCGI) also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.

In a statement, the Hyderabad-based Pharma company Bharat Biotech said that it had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group.

The clinical trials conducted in the paediatric population between June 2021 to September 2021 have shown robust safety, reactogenicity, and immunogenicity.

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children alike. Covaxin is a ready-to-use liquid vaccine, stored at 2-8 degrees Celsius, with 12 months shelf life and a multi-dose vial policy.

Moreover, Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company’s Phase 2 and 3 clinical trials for COVAXIN (BBV152).

Chairman, CEO, and Co-Founder of Ocugen Inc., Dr Shankar Musunuri, said, “We’re extremely pleased that we can proceed with our clinical trials for COVAXIN, our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority.” (ANI)

 

 

Topics: Bharat BiotechWHOIndiaGermanyCOVAXIN
Share1TweetSendShareSend
Previous News

ED raids multiple locations in Maharashtra linked to Shiv Sena minister Anil Parab in money laundering case

Next News

Pakistan on the boil as Imran Khan’s ‘march to chaos’ continues

Related News

Tamil Nadu: Call for partition & separate statehood a new normal in DMK rule

Tamil Nadu: Call for partition & separate statehood a new normal in DMK rule

Universal Hindutva: Dismantling Hinduphobia

‘To the Fourth of July’: A poem written by Swami Vivekananda 4 years before his Mahasamadhi!

All Above 18 Eligible for Vaccination From May 1, Announces Centre

India’s COVID vaccination coverage exceeds 197.95 cr

Prime Minister Narendra Modi speaks to Russian President Putin on phone

Amid tough balancing roles, PM Modi speaks to Putin

Discounting Black Sheeps, Country Stands United to Fight the New Wave of Covid-19

India reports 17,070 new COVID cases in last 24 hours

‘Rape, pregnant or love affair? Mamata Banerjee on Nadia rape case; BJP lashes out at CM’s ‘shameful’ remark

‘Centre wants to give jobs to BJP workers’: CM Mamata Banerjee on Agnipath Scheme

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

UP: 36 arrested, 3 FIRs registered in Kanpur violence

#FridayFrenzy: Man who allegedly funded June 3 Kanpur violence arrested

China’s Premier Li Keqiang issues third warning over economic growth amid COVID-19 outbreak

President Xi’s presence in Hong Kong would seek to send important signals

Assam: Kabul Khan along with 3 others arrested for damaging river embankment leading to a devastating flood in Cachar

Assam: Kabul Khan along with 3 others arrested for damaging river embankment leading to a devastating flood in Cachar

“It’s made at the behest of the British to plunder people”: Outrage over Kerala Minister’s remarks against Constitution

“It’s made at the behest of the British to plunder people”: Outrage over Kerala Minister’s remarks against Constitution

Govt to give a mega push to ‘Justice at the door-steps’ programme

Supreme Court went beyond “Laxman Rekha,” says the open letter to CJI N V Ramana 

Eknath Shinde: Man who stole the March

Eknath Shinde: Man who stole the March

Jauhar University case: ED summons SP leader Azam Khan, his wife and son

Jauhar University case: ED summons SP leader Azam Khan, his wife and son

Tamil Nadu: Call for partition & separate statehood a new normal in DMK rule

Tamil Nadu: Call for partition & separate statehood a new normal in DMK rule

Discomforted Chinese nationals under Xi Jinping’s oppressive governance seeking asylum abroad

Discomforted Chinese nationals under Xi Jinping’s oppressive governance seeking asylum abroad

Gujarat Riots: The Archetypal Elite of the pre-Modi Era

Gujarat Riots: The Archetypal Elite of the pre-Modi Era

  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping Policy

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Culture
  • Sports
  • Business
  • RSS in News
  • Special Report
  • Sci & Tech
  • Entertainment
  • Education
  • Books
  • Interviews
  • Travel
  • Health
  • Obituary
  • Subscribe
  • Advertise
  • Circulation
  • About Us
  • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Refund and Cancellation

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies